LDCT Lung Screening for Early Detection of Lung Cancer
Palo Alto (17 mi)Overseen byDaniel Carrizosa, MD
Age: 18 - 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: N/A
Recruiting
Sponsor: Daniel Carrizosa
No Placebo Group
Approved in 3 jurisdictions
Trial Summary
What is the purpose of this trial?Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.
Is Mobile Low-dose Computed Tomography (LDCT) Screening a promising treatment for early detection of lung cancer?Yes, Mobile Low-dose Computed Tomography (LDCT) Screening is a promising treatment for early detection of lung cancer. It helps find lung cancer early, especially in people at high risk, like smokers, which can reduce the number of deaths from lung cancer.145911
What safety data exists for LDCT lung cancer screening?LDCT lung cancer screening has been shown to reduce lung cancer mortality by 20% in high-risk populations. However, safety concerns include increased radiation exposure, overdiagnosis of indolent tumors, and high numbers of false-positive results, which can lead to unnecessary procedures and potential complications. These risks and benefits are considered in current recommendations for LDCT screening.123613
What data supports the idea that LDCT Lung Screening for Early Detection of Lung Cancer is an effective treatment?The available research shows that LDCT lung screening is effective in reducing deaths from lung cancer. For example, the National Lung Screening Trial demonstrated that using LDCT can lower lung cancer mortality. Additionally, studies like the one from the Gdańsk experience highlight LDCT as a promising tool for reducing deaths from lung cancer. These findings suggest that LDCT screening is a valuable method for early detection and can save lives by catching cancer early when it is more treatable.5781012
Do I have to stop taking my current medications for the trial?The trial protocol does not specify whether you need to stop taking your current medications.
Eligibility Criteria
This trial is for people aged 40-54 who have a significant smoking history (at least 30 pack years), are currently smoking or quit within the last 15 years, and can understand English/Spanish. They must consent to share health information and follow study procedures. Those with past lung cancer diagnosis, CT scan contraindications, or pregnancy cannot join.Inclusion Criteria
I am between 40 and 54 years old.
I can read and understand either English or Spanish.
Exclusion Criteria
I was diagnosed with lung cancer within the last 5 years.
Treatment Details
The study tests if lowering the age for Low-dose Computed Tomography (LDCT) screening can help detect lung cancer earlier in smokers or recent quitters aged 40-54. This follows evidence that LDCT improves survival rates in older individuals.
1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Mobile Low-dose Computed Tomography (LDCT) Screening
Mobile Low-dose Computed Tomography (LDCT) Screening is already approved in United States, European Union, Canada for the following indications:
🇺🇸 Approved in United States as Low-dose CT Screening for:
- Lung cancer screening for high-risk populations aged 55 and older
- Experimental use for ages 40-54 in specific studies
🇪🇺 Approved in European Union as LDCT Screening for:
- Lung cancer screening for high-risk populations aged 55 and older
🇨🇦 Approved in Canada as Low-dose CT Screening for:
- Lung cancer screening for high-risk populations aged 55 and older
Find a clinic near you
Research locations nearbySelect from list below to view details:
Levine Cancer InstituteCharlotte, NC
Loading ...
Who is running the clinical trial?
Daniel CarrizosaLead Sponsor
Wake Forest University Health SciencesLead Sponsor
Leon Levine FoundationCollaborator
References
[Application value of low-dose computed tomography for the screening of lung cancer in high-risk group]. [2016]To analyze the value of low-dose computed tomography (LDCT) in early screening of lung cancer in high-risk group.
Effective use of low-dose computed tomography lung cancer screening. [2016]Lung cancer screening programs for high-risk populations using low-dose computed tomography (LDCT) have been shown by a class I clinical trial to reduce lung cancer mortality by 20%. We present an overview of randomized and nonrandomized lung cancer screening trials and review some of the arguments advocating for or against the widespread implementation of such a screening program. Concerns regarding the use of LDCT screening for lung cancer include increased risk from radiation exposure, overdiagnosis of indolent tumors, and high numbers of false-positive results, which may increase patient anxiety and result in unnecessary procedures with potential complications. Current recommendations regarding diagnostic criteria and workup of positive screens as well as the risks and benefits of using LDCT for lung cancer screening are provided.
Computed tomography screening for lung cancer: where are we now? [2021]Low-dose computed tomography (LDCT) screening has been shown to result in detection of earlier-stage lung cancers, with a 20% reduction in cancer-related deaths. LDCT screening offers significant potential benefits to selected patients; however, many questions remain, including questions about the applicability of lung cancer screening in clinical practice.
A meta-analysis: is low-dose computed tomography a superior method for risky lung cancers screening population? [2017]Low-dose computed tomography (LDCT) has been proposed to be a new screening method to discover lung cancers in an early stage, especially those patients who are in a high risk of lung cancer. The primary objective of this meta-analysis is to systematically review the effect of LDCT on screening for lung cancers among the risky population who are older than 49 years old and with smoking exposure.
Results of an open-access lung cancer screening program with low-dose computed tomography: the Gdańsk experience. [2019]Lung cancer screening with low-dose computed tomography (LDCT) is one of the most promising tools for reducing mortality from lung cancer.
An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice. [2022]Annual low-radiation-dose computed tomography (LDCT) screening for lung cancer has been shown to reduce lung cancer mortality among high-risk individuals and is now recommended by multiple organizations. However, LDCT screening is complex, and implementation requires careful planning to ensure benefits outweigh harms. Little guidance has been provided for sites wishing to develop and implement lung cancer screening programs.
Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis. [2022]Targeting low-dose computed tomography (LDCT) for lung cancer screening to persons at highest risk for lung cancer mortality has been suggested to improve screening efficiency.
Low-dose Lung Cancer Screening at an Academic Medical Center: Initial Experience and Dose Reduction Strategies. [2019]Implementation of low dose computed tomography (LDCT) lung cancer screening programs has followed the demonstration of reduced lung cancer mortality in the National Lung Screening Trial and subsequent consensus screening recommendations. Here we aim to assess the initial results of a screening program at an academic medical center, to discuss the challenges of implementing such a program, and suggest strategies for reducing patient dose.
Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models. [2022]Low-dose CT (LDCT) is currently used in lung cancer screening of high-risk populations for early lung cancer diagnosis. However, 96% of individuals with detected nodules are false positives.
Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group. [2020]Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy.
Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. [2021]Lung Cancer (LC) screening with low dose chest computed tomography (LDCT) in smokers reduces LC mortality. Patients with Obstructive Lung Disease (OLD) are at high risk for LC. The potential effect of LC screening in this population is unknown.
Low-Dose Computed Tomography: Effects of Oncology Nurse Navigation on Lung Cancer Screening. [2021]Low-dose computed tomography (LDCT) lung cancer screening is an evidence-based and reimbursable strategy to decrease lung cancer and all-cause mortality in qualifying patients, but there remains low use and variation in providers' LDCT screening, ordering, and referring knowledge.
Patient Adherence in an Academic Medical Center's Low-dose Computed Tomography Screening Program. [2023]Low-dose computed tomography (LDCT) screening is an important tool for reducing lung cancer mortality. This study describes a single center's experience with LDCT and attempts to identify any barriers to compliance with standard guidelines.